Korean J Anesthesiol Search

CLOSE


Korean J Anesthesiol > Volume 79(4); 2026 > Article
Running title Perioperative multimodal analgesia
Authors Initials WN Kuwamoto, GC Eddy, ER Mariano
Kuwamoto, Eddy, Mariano, and Schwenk: An update on the role of multimodal analgesia in perioperative pain management

Abstract

Multimodal analgesia has become a foundational principle of acute perioperative pain management and enhanced recovery and involves the application of nonpharmacologic, pharmacologic, and/or interventional techniques. The overall goal of this approach is to apply a combination of different modalities that target discrete points along the pain pathway and thereby avoid the overreliance on opioids and associated side effects. Since our review in 2018, there have been significant developments that have prompted an updated review of multimodal analgesia. In this article, we identify and summarize important trends that influence the current approach to acute perioperative pain management as well as provide an updated clinical guide on multimodal analgesia with an emphasis on novel therapies. While a continued emphasis on multimodal opioid-sparing analgesia remains, additional evidence, newer regional techniques, and novel agents such as suzetrigine have emerged since our last review and have expanded options for perioperative pain management. In addition, special situations require specific recommendations, such as when designing a perioperative pain management plan for surgical patients who have opioid tolerance or live with opioid use disorder. These complex patients are at a higher risk for poor postoperative pain control and other adverse outcomes. This review includes suggested guidance on tailoring multimodal analgesia in this population with patient-specific therapies that can be added for appropriate indications and are supported by available evidence and guidelines.

Introduction

In the modern era of surgical care, routine use of multimodal analgesia has become a foundational principle of acute perioperative pain management [1]. Within the United States, the administration of multimodal analgesia for eligible surgical cases is a national quality measure [2], one of very few quality measures that directly relate to anesthesiologists. Implementation of multimodal analgesia has been associated with decreases in perioperative opioid use and complications after major surgery [3]. Given the data available at the time, we asserted in a 2018 review that designing an ideal perioperative pain management strategy should always start with multimodal analgesia [4], and we believe that this still holds true today in spite of the many advances in surgery, anesthesiology, and perioperative medicine in recent years.
At a minimum, multimodal analgesia is defined as the use of two or more analgesic therapies with different mechanisms of action with the goal of providing effective pain control [4], while avoiding the overreliance on opioids and associated opioid-related adverse effects. These modalities may be nonpharmacologic, pharmacologic, or interventional, with interventional techniques varying in their invasiveness and duration of action. When used optimally in combination, the elements of a multimodal analgesic regimen target different and discrete points along the pain pathway and may be adjusted to treat patients with specific pain subtypes [4,5].
In our initial review of multimodal analgesia, we addressed the core pharmacologic and interventional elements, which included the following nonopioid systemic analgesics: acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors, gabapentinoids, ketamine, magnesium, local anesthetics via surgical infiltration or peripheral nerve blocks, and lidocaine infusions. We also discussed appropriate indications and the judicious use of opioids [4]. However, healthcare worldwide continues to evolve, and there have been significant developments that have prompted this updated review of multimodal analgesia. In this paper, we provide an overview of important trends that influence the current approaches to acute perioperative pain management and an updated clinical guide on multimodal analgesia with an emphasis on new therapies.

The expansion of outpatient surgery

In recent years, given the rising costs of healthcare and projected increases in the number of total joint arthroplasty procedures performed per year, there has been a notable interest in transitioning arthroplasty to the outpatient setting with same-day discharge in many parts of the world [6]. In the United States, the proportion of outpatient arthroplasty has increased from < 1% in 2016 to approximately 20% in 2021 [7], although this change is not without risks [8]. The COVID-19 pandemic, which occurred after the publication of our original article [4], forced the temporary stoppage of all elective surgical procedures. Resuming those procedures during the ongoing pandemic prompted the re-evaluation of the risks and benefits of hospitalization, particularly the potential exposure to an infectious disease after undergoing a prosthetic joint implantation. This resulted in an increase in outpatient arthroplasty [9].
For patients discharged home on the same day after arthroplasty, perioperative pain management is a significant challenge given that intravenous analgesics are not available. Effective multimodal pain management in the outpatient setting should be easy to self-administer, promote early mobility and functional independence, minimize central nervous system adverse effects, and promote sleep [10].

Growing awareness of differential postoperative pain trajectories

Despite the wide range of therapeutic interventions available for postoperative pain management, there is a relative paucity of population-based observational data on postoperative pain trajectories [11]. The data available suggest that postoperative pain may vary both between surgical procedures and between individual patients having the same procedure [11,12]. Ideally, the proper application of acute perioperative pain management should be procedure- and person-specific based on the expected trajectories of pain and recovery after surgery.
Although advances in clinical pain research have not yet reached the point of individualized perioperative pain management plans, there is evidence to suggest that certain patient phenotypes may respond differently to specific interventions, and certain patient ‘tiers’ may require more analgesic modalities in their multimodal regimen than others. Vasilopoulos et al. [12] identified younger age, female sex, anxiety, and frequent pain behaviors, which were present on preoperative assessment, as risk factors for the high postoperative pain trajectory group in their study. This suggests that intentional preoperative pain assessment may be able to help guide the design of perioperative pain management regimens based on the ‘tier’ of patient. Preoperative identification of a particular pain phenotype, through examination of factors like baseline pain sensitivity, psychological comorbidities (e.g., anxiety, pain catastrophizing), and social support, may enable physicians to identify those patients at higher risk for severe acute pain and even tailor the perioperative pain management plan to their needs [13,14].

The emergence of fascial plane blocks for thoracic and abdominal surgeries

One of the most substantial changes to perioperative analgesia since our last review is the emergence of fascial plane blocks as alternatives to thoracic epidural analgesia for surgeries in the chest and abdomen. Fascial plane blocks target distal sensory and motor branches of peripheral nerves and may be useful as part of multimodal analgesia within enhanced recovery protocols, although they appear to be more effective for somatic pain than visceral pain [15–17]. Many novel blocks have been described including: the transversus abdominis plane, rectus sheath, quadratus lumborum, erector spinae plane (ESP), serratus anterior plane, and interpectoral/pecto-serratus plane (i.e., ‘Pecs II’) blocks [18]. One potential advantage of these blocks over traditional thoracic epidural analgesia in the setting of enhanced recovery is the avoidance of sympathectomy, which preserves blood pressure and decreases the administration of intravenous fluid [19,20]. Although data are limited, fascial plane blocks are performed in locations that are further away from the spinal cord, which decreases concern for clinically-significant bleeding complications that are generally associated with epidurals, especially when patients may be prescribed anticoagulant or antiplatelet drugs postoperatively [21,22].
In breast and thoracic surgery, a meta-analysis of randomized controlled trials found that the serratus anterior plane block reduced both acute and chronic postsurgical pain [23]. A meta-analysis of ESP block studies found that they reduced postoperative pain after thoracic surgery similar to paravertebral blocks [24]. For patients undergoing abdominal surgery, there is mixed evidence regarding fascial plane blocks, with some articles supporting benefits of certain fascial plane blocks in pain and opioid reduction [25–27]; however, a recent randomized clinical trial reported no improvement in analgesia with both plain and liposomal bupivacaine for transversus abdominis plane blocks [28]. While epidural analgesia remains an established gold standard regional analgesic technique, particularly in major thoracic and abdominal surgeries, the trend in modern surgical practice continues to move towards less invasive techniques and rapid postoperative recovery, which has promoted the development of fascial plane blocks as alternatives with society guidelines supporting their use [29].

Routine or foundational elements of multimodal analgesia

Nonpharmacologic modalities

Nonpharmacologic modalities are foundational in multimodal analgesia (Table 1) and should be routinely employed unless contraindicated [5,30]. Examples include physical therapy, cryotherapy, compression, acupuncture, and transcutaneous electrical nerve stimulation, although robust evidence-based guidelines for nonpharmacologic analgesia have not been established [5]. Cognitive behavioral therapy may also have a role in mitigating some of the deleterious effects of postoperative pain in some patients [31]. These approaches support aspects of the biopsychosocial model of pain and may have a role in postoperative recovery from surgery.
Setting realistic expectations and providing patient and caregiver education regarding pain management prior to surgery are powerful nonpharmacologic interventions. While a pain-free postoperative experience is rarely feasible, there is evidence that positive preoperative expectations may lead to decreased postoperative pain [32]. Patients should be counseled that achieving a tolerable level of pain, one that allows for early activity and participation in rehabilitation, is a more realistic and meaningful goal [5].

Basic systemic nonopioid analgesics

Although covered in greater depth in our original review [4], acetaminophen and NSAIDs or COX-2 inhibitors continue to be recommended as routine components of multimodal analgesia (Table 1) [30,33]. In addition to the established effectiveness and safety for acetaminophen [34] and NSAIDs in the immediate postoperative period [35,36], these drugs are available in generic low-cost formulations. The potential role of NSAIDs in postoperative bleeding has been a controversial topic, but a meta-analysis by Bongiovanni et al. that included 74 articles showed no increase in risk for hematoma, return to the operating room for bleeding, or blood transfusion in patients who received NSAIDs when compared to patients who did not [37]. Caution is still warranted when considering the use of NSAIDs in patients with preexisting renal dysfunction [38].

Local anesthetics

Local anesthetics should be routinely administered in some form in any surgical procedure unless contraindicated (e.g., allergy) (Table 1). Options include infiltration by the surgeon at or near the surgical site, a peripheral nerve or fascial plane block, or a neuraxial block. Peripheral regional techniques can reduce postoperative pain and opioid use in various procedures [39–41], and the selection of technique, titratability, and duration of action (i.e., single-injection or catheter, use of adjuvants or extended-release formulations) should ideally be guided by the anticipated postoperative pain trajectory and expectations for recovery (e.g., location, activity). An extensive review of the various regional analgesic options is beyond the scope of this article.
Intravenous lidocaine infusions have been applied for perioperative analgesia and may be useful for cases in which a regional block is not provided [42,43]. Intravenous lidocaine has been incorporated into enhanced recovery protocols [44,45], with short-term dose-dependent benefits on postoperative pain [46]. An international consensus group did not provide a definitive recommendation regarding perioperative lidocaine infusions but did emphasize the importance of tailoring their use to individual patients and surgeries [43]. Lidocaine infusions have been shown to reduce inflammation [47], and a recent randomized clinical trial found reductions in both inflammation and pulmonary complications after thoracic surgery [48].

Opioids

Opioids remain an important element of multimodal analgesia, particularly as treatment for visceral pain, which may not be covered by other modalities (Table 1) [17]. In acute perioperative pain management, there are international consensus recommendations regarding safe opioid administration and avoidance of harm [49]. Some key recommendations include: a preoperative assessment of chronic opioid use; incorporation of patient function rather than pain intensity ratings alone in assessments of analgesic effectiveness; limiting the number of tablets prescribed at discharge; not initiating long-acting opioids in opioid-naive patients; counseling on the risks of opioids and safe disposal practices at discharge; and avoidance of automatic opioid refills. Following existing perioperative pain management guidelines [29,50] and practicing good opioid stewardship are highly recommended to maximize benefits and minimize complications.

Next level elements of multimodal analgesia that deserve special consideration

In addition to the routine or foundational elements of multimodal analgesia, there are classes of pain therapies or new drugs that may be employed for specific indications based on the patient and/or procedure (Table 1).

Selective voltage-gated sodium channel inhibitor

Suzetrigine is a new drug recently approved in the United States that selectively inhibits the voltage-gated sodium channel NaV1.8 in peripheral nerves and dorsal root ganglion sensory neurons, which are partially responsible for hyperexcitability. It is approved by the Food and Drug Administration for acute postoperative pain and is the first medication in this new class of nonopioid analgesics [51]. Suzetrigine is not thought to affect the central nervous system or interact with local anesthetics, which are non-selective sodium channel blockers [52,53]. In Phase 3 studies, suzetrigine has been demonstrated to produce superior analgesia to placebo and comparable analgesia to hydrocodone/acetaminophen with potentially fewer adverse effects [54]. It is currently being studied for diabetic peripheral neuropathy, a classic neuropathic chronic pain model [55]. Although promising, given its novel mechanism of action, its role in routine perioperative pain management, especially when used in combination with other established agents in a multimodal regimen, is not yet known but will be actively studied in the coming years.

Serotonin-norepinephrine reuptake inhibitor

As a serotonin-norepinephrine reuptake inhibitor, duloxetine is approved for the treatment of major depressive disorder, generalized anxiety disorder, fibromyalgia, chronic musculoskeletal pain, and diabetic peripheral neuropathy. It may be considered in patients with overlapping pain and mental health disorders but is contraindicated in individuals taking monoamine oxidase inhibitors and those with hepatic failure or severe renal impairment. Clinicians should monitor patients for suicidal ideation, serotonin syndrome, and potential drug interactions, particularly in elderly, pregnant, or breastfeeding patients [56]. Duloxetine as a perioperative analgesic is supported by two meta-analyses [57,58], which included total joint arthroplasty, but another meta-analysis did not find a clinically-important improvement in pain [59]. Therefore, duloxetine should not be routinely included in multimodal analgesic protocols, but may be considered as an added element for special indications in patients with the indicated chronic pain diagnoses having surgery, contraindications to other analgesic medications, or comorbid pain and mental health disorders.

Gabapentinoids

Gabapentinoids (e.g., gabapentin and pregabalin) act on voltage-dependent calcium channels to modulate excitatory neurotransmission centrally and peripherally [60]. These agents may reduce postoperative pain and opioid requirements, especially in patients with a neuropathic etiology of pain [61]. Respiratory depression can occur when gabapentinoids and opioids are combined [62], and side effects such as sedation, dizziness, and delirium may be more pronounced in the elderly [63]. Given available data which do not strongly support the analgesic benefit of gabapentinoids [64–66], they should not be given routinely in perioperative pain management. They may be appropriate to use in special cases, such as when patients are already taking them chronically or in select surgeries where nerve injury is likely, but duration of therapy should be limited with careful monitoring for side effects.

N-methyl-D-aspartate (NMDA) receptor antagonists

Ketamine is an NMDA receptor antagonist but also modulates acetylcholine, gamma-aminobutyric acid, and opioid receptors, as well as voltage-gated calcium channels, making it a versatile analgesic [67]. It can be effective for patients undergoing painful surgery, are opioid-tolerant, or have a history of substance use disorder or depression [68–70]. Adverse effects when using subanesthetic doses are mild and generally tolerable [71]. Magnesium sulfate is a noncompetitive NMDA receptor antagonist. It has been shown to reduce postoperative pain, opioid requirements, and may prolong spinal blockade when used as an adjuvant with morphine or ketamine [4,30]. It has also been found to reduce intraoperative anesthetic requirements [72]. It is generally well tolerated at perioperative doses, although care should be taken in patients with renal insufficiency due to the risk of accumulation and toxicity. Adverse effects may include hypotension, bradycardia, nausea, vomiting, and, at higher concentrations, neuromuscular weakness, respiratory depression, arrhythmias, and prolonged time to tracheal extubation [73].

Special populations

Patients with opioid tolerance

Opioid-tolerant patients display altered physiology compared to opioid-naive patients. Some of the changes that occur include hypersensitivity to painful stimuli [74] and sleep-disordered breathing [75], which encompasses both obstructive and central sleep apnea. Opioid-tolerant patients experience worse perioperative outcomes, including inadequate analgesia, higher readmission rates, greater healthcare costs, and reduced odds of returning to work [76–79]. Realistic pain expectations should be discussed at the time of surgical planning, and every effort should be made to communicate and plan with the patient’s opioid prescriber, specifically around postoperative opioid prescribing upon discharge and outpatient follow-up. Multimodal analgesia is recommended for opioid-tolerant patients, both to improve analgesia and to minimize dose escalations of opioids. Of all the medications available to add to a routine multimodal regimen, ketamine has been shown to provide opioid-reducing analgesia in this patient population [80]. When available, an acute pain service can help improve analgesia, suggest opioid alternatives, and work with surgeons and other healthcare staff to develop safe opioid discharge regimens [78,79,81].

Patients with opioid use disorder

In the United States, overdose deaths from prescription opioids have flattened and even declined in recent years [82]. However, the overall opioid-related overdose death rate has continued to climb, largely driven by illicit fentanyl and other synthetic opioids. Patients living with opioid use disorder (OUD) can present challenges in the perioperative period, but there have been important recent advances. The American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) strongly recommends the involvement of acute pain services in the perioperative care of patients with OUD [39]. In general, patients who are prescribed buprenorphine (partial mu opioid agonist and kappa antagonist) should continue it throughout the perioperative period for pain management and to reduce the risk of relapse [83]. This is a change from prior recommendations that suggested stopping the drug several days prior to painful surgeries [84].
Buprenorphine can be a very effective analgesic and several clinical studies [85,86] have demonstrated comparable analgesia between buprenorphine and morphine. If additional full mu-receptor agonists are indicated in a patient taking buprenorphine in the immediate perioperative period, hydromorphone or sufentanil may be used as these agents have high binding affinities for the mu- receptor [87]. While buprenorphine confers an overall low risk of respiratory depression, it is still possible, especially when combined with benzodiazepines and other sedating medications [88].
Other medications for OUD that may be encountered in the perioperative period include methadone and naltrexone. Similar to the perioperative management of buprenorphine, preoperative methadone dosing should be continued throughout the perioperative period, including the day of surgery [88]. One challenge with continuing outpatient methadone for OUD that is administered by a methadone clinic is that the dose may not be known by the patient, so outreach to the clinic will be necessary. Methadone can cause respiratory depression, particularly after a dose increase in a patient on a previously stable dose [88]. Monthly extended-release intramuscular naltrexone for OUD presents a unique challenge in the perioperative period due to the regular cadence of injections and long duration of action. Although experience and evidence remain limited, experts suggest that full mu-receptor agonists may only be partially effective during the first two to three weeks after the injection [88].
There is no single “best” approach at managing postoperative pain in this population, but the overall strategy should focus on maximizing nonopioid agents, incorporating regional anesthesia and analgesia whenever possible, using the lowest effective doses of opioids (full mu agonists) as rescue agents, and coordination with the physician prescribing OUD treatment before surgery and before discharge [89–91].
Fig. 1 shows suggested management tips for patients with opioid tolerance or OUD based throughout the phases of surgical care.

Conclusions

While a continued emphasis on multimodal analgesia remains, since our last review in 2018, additional evidence, newer regional techniques, and novel agents such as suzetrigine have emerged, and have expanded options for perioperative pain management. Special consideration should be given to designing perioperative pain management plans for surgical patients who take chronic opioids or live with OUD, both of whom are at higher risk for poorly controlled pain and worse postoperative outcomes. For these special populations and all patients who undergo surgery, designing the ideal perioperative pain management plan depends on consistent implementation of multimodal analgesia, founded in evidence-based modalities that can be used routinely and augmented by patient-specific therapies that can be added for appropriate indications.

Acknowledgments

ERM is a member of the editorial board of the Korean Journal of Anesthesiology. ERM’s contribution to this work is supported with resources and the use of facilities at the Veterans Affairs Palo Alto Health Care System (Palo Alto, California, USA). The contents do not represent the views of the Department of Veterans Affairs or the United States Government.

Funding

None.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Data Availability

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Author Contributions

Whitney N. Kuwamoto (Writing – original draft; Writing – review & editing)

Grace C. Eddy (Visualization; Writing – original draft; Writing – review & editing)

Edward R. Mariano (Conceptualization; Methodology; Visualization; Writing – original draft; Writing – review & editing)

Eric S. Schwenk (Conceptualization; Methodology; Resources; Supervision; Writing – original draft; Writing – review & editing)

Fig. 1.
Suggested perioperative pain management of patients with opioid tolerance or opioid use disorder (OUD) throughout the phases of surgical care.
kja-26304f1.jpg
Table 1.
Select Elements of Perioperative Multimodal Analgesia with Examples, Recommendations for Use, and Special Considerations
Class Examples Recommended use Special considerations
Nonpharmacologic Patient education, physical therapy, cryotherapy, compression, acupuncture, transcutaneous electrical nerve stimulation Routine unless contraindicated Robust, evidence-based guidelines are lacking; some modalities may not be available at every hospital or surgery center
Acetaminophen Also known as paracetamol Routine unless contraindicated May be given orally or intravenously; reduce dose in patients with chronic liver disease
Nonsteroidal anti-inflammatory drugs or COX-2 inhibitors Ibuprofen, ketorolac, celecoxib Routine unless contraindicated COX-2 inhibitors are preferred for patients with history of peptic ulcer disease
Local anesthetics Neuraxial block (e.g., epidural), peripheral nerve or fascial plane block, infiltration by surgeon, intravenous lidocaine infusion Routine unless contraindicated Regional analgesia is recommended by guidelines but may not always be available; intravenous lidocaine may have benefits in intra-thoracic and intra-abdominal surgeries when regional analgesia is not performed
Opioids Morphine, hydromorphone, fentanyl, sufentanil, methadone Use for appropriate indications Effective for visceral pain; follow recommendations to minimize potential opioid-related harm
NaV1.8 inhibitor Suzetrigine Use for appropriate indications New class of nonopioid analgesic for acute postoperative pain; targets peripheral nerves
NMDA receptor antagonists Ketamine, magnesium sulfate Use for appropriate indications Generally, well tolerated although may produce side effects at higher concentrations (e.g., vivid dreams or psychosis with ketamine, muscular weakness with magnesium)
Gabapentinoids Gabapentin, pregabalin Use for appropriate indications May be useful for neuropathic pain; limited by side effects (e.g., sedation, confusion) especially in the elderly
Serotonin-norepinephrine reuptake inhibitor Duloxetine Use for appropriate indications Used to treat depression, anxiety, fibromyalgia, and diabetic neuropathy; limited evidence in perioperative setting

COX-2: cyclo-oxygenase-2, NaV: voltage-gated sodium channel, NMDA: N-methyl-D-aspartate.

References

1. Mariano ER, Dickerson DM, Szokol JW, Harned M, Mueller JT, Philip BK, et al. A multisociety organizational consensus process to define guiding principles for acute perioperative pain management. Reg Anesth Pain Med 2022; 47: 118-27.
crossref pmid
2. Centers for Medicare & Medicaid Services. Quality ID #477: Multimodal Pain Management [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2022 [cited 2026 Mar 19]. Available from https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_477_MIPSCQM.pdf

3. Memtsoudis SG, Poeran J, Zubizarreta N, Cozowicz C, Mörwald EE, Mariano ER, et al. Association of multimodal pain management strategies with perioperative outcomes and resource utilization: a population-based study. Anesthesiology 2018; 128: 891-902.
crossref pmid
4. Schwenk ES, Mariano ER. Designing the ideal perioperative pain management plan starts with multimodal analgesia. Korean J Anesthesiol 2018; 71: 345-52.
crossref pmid pmc pdf
5. Kandarian BS, Elkassabany NM, Tamboli M, Mariano ER. Updates on multimodal analgesia and regional anesthesia for total knee arthroplasty patients. Best Pract Res Clin Anaesthesiol 2019; 33: 111-23.
crossref pmid
6. Bert JM, Hooper J, Moen S. Outpatient total joint arthroplasty. Curr Rev Musculoskelet Med 2017; 10: 567-74.
crossref pmid pmc pdf
7. Reisinger L, Cozowicz C, Poeran J, Zhong H, Illescas A, Giannakis P, et al. Trends in comorbidities and complications among patients undergoing elective total hip and knee arthroplasty in the USA. Anaesthesia 2025; 80: 543-50.
crossref pmid
8. French JM, Deere K, Sayers A, Whitehouse MR. Day case hip and knee replacement in England: a population-based cohort study using linked National Joint Registry and Hospital Episode Statistics data. BMC Med 2025; 23: 564.
crossref pmid pmc pdf
9. Sandoval LA, Reiter CR, Wyatt PB, Satalich JR, Ernst BS, O'Neill CN, et al. Outpatient total knee arthroplasty has become more frequent since the onset of the COVID-19 pandemic without an increase in early post-operative complications. J Arthroplasty 2025; 40: 1992-2000.e2.
crossref pmid
10. Li J, Rubin LE, Mariano ER. Essential elements of an outpatient total joint replacement programme. Curr Opin Anaesthesiol 2019; 32: 643-8.
crossref pmid
11. Mariano ER, El-Boghdadly K, Ilfeld BM. Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine. Anaesthesia 2021; 76: 165-9.
crossref pdf
12. Vasilopoulos T, Wardhan R, Rashidi P, Fillingim RB, Wallace MR, Crispen PL, et al. Patient and procedural determinants of postoperative pain trajectories. Anesthesiology 2021; 134: 421-34.
crossref pmid pmc pdf
13. Schreiber KL, Wilson JM, Chen YK. Recognizing pain phenotypes: biopsychosocial sources of variability in the transition to chronic postsurgical pain. Reg Anesth Pain Med 2025; 50: 86-92.
crossref pmid
14. Castaño-Asins JR, Barceló-Soler A, Royuela-Colomer E, Sanabria-Mazo JP, García V, Neblett R, et al. Effectiveness of peri-operative psychological interventions for the reduction of postsurgical pain intensity, depression, anxiety and pain catastrophising: a systematic review and meta-analysis. Eur J Anaesthesiol 2025; 42: 609-25.
crossref pmid
15. Chin KJ, Versyck B, Elsharkawy H, Rojas Gomez MF, Sala-Blanch X, Reina MA. Anatomical basis of fascial plane blocks. Reg Anesth Pain Med 2021; 46: 581-99.
crossref pmid
16. Chin KJ, Malhas L, Perlas A. The erector spinae plane block provides visceral abdominal analgesia in bariatric surgery: a report of 3 cases. Reg Anesth Pain Med 2017; 42: 372-6.
crossref pmid pmc
17. Boezaart AP, Smith CR, Chembrovich S, Zasimovich Y, Server A, Morgan G, et al. Visceral versus somatic pain: an educational review of anatomy and clinical implications. Reg Anesth Pain Med 2021; 46: 629-36.
crossref pmid
18. El-Boghdadly K, Wolmarans M, Stengel AD, Albrecht E, Chin KJ, Elsharkawy H, et al. Standardizing nomenclature in regional anesthesia: an ASRA-ESRA Delphi consensus study of abdominal wall, paraspinal, and chest wall blocks. Reg Anesth Pain Med 2021; 46: 571-80.
crossref pmid
19. Xu M, Hu J, Yan J, Yan H, Zhang C. Paravertebral block versus thoracic epidural analgesia for postthoracotomy pain relief: a meta-analysis of randomized trials. Thorac Cardiovasc Surg 2022; 70: 413-21.
crossref pmid
20. Krige A, Brearley SG, Mateus C, Carlson GL, Lane S. A comparison between thoracic epidural analgesia and rectus sheath catheter analgesia after open midline major abdominal surgery: randomized clinical trial. BJS Open 2022; 6: zrac055.
crossref pmid pmc pdf
21. Toscano A, Capuano P, Galata M, Tazzi I, Rinaldi M, Brazzi L. Safety of ultrasound-guided serratus anterior and erector spinae fascial plane blocks: a retrospective analysis in patients undergoing cardiac surgery while receiving anticoagulant and antiplatelet drugs. J Cardiothorac Vasc Anesth 2022; 36: 483-8.
crossref pmid
22. Adhikary SD, Prasad A, Soleimani B, Chin KJ. Continuous erector spinae plane block as an effective analgesic option in anticoagulated patients after left ventricular assist device implantation: a case series. J Cardiothorac Vasc Anesth 2019; 33: 1063-7.
crossref pmid
23. Meng J, Zhao HY, Zhuo XJ, Shen QH. Postoperative analgesic effects of serratus anterior plane block for thoracic and breast surgery: a meta-analysis of randomized controlled trials. Pain Physician 2023; 26: E51-62.
crossref pmid
24. Capuano P, Hileman BA, Martucci G, Raffa GM, Toscano A, Burgio G, et al. Erector spinae plane block versus paravertebral block for postoperative pain management in thoracic surgery: a systematic review and meta-analysis. Minerva Anestesiol 2023; 89: 1042-50.
crossref pmid
25. Fanelli A, Torrano V, Cozowicz C, Mariano ER, Balzani E. The opioid sparing effect of erector spinae plane block for various surgeries: a meta-analysis of randomized-controlled trials. Minerva Anestesiol 2021; 87: 903-14.
crossref pmid
26. Turan A, Cohen B, Elsharkawy H, Maheshwari K, Soliman LM, Babazade R, et al. Transversus abdominis plane block with liposomal bupivacaine versus continuous epidural analgesia for major abdominal surgery: The EXPLANE randomized trial. J Clin Anesth 2022; 77: 110640.
crossref pmid
27. Desai N, El-Boghdadly K, Albrecht E. Epidural vs. transversus abdominis plane block for abdominal surgery - a systematic review, meta-analysis and trial sequential analysis. Anaesthesia 2021; 76: 101-17.
crossref pmid pdf
28. Turan A, Ali Sakr Esa W, Brooker J, Rosen MJ, Ekrami E, Tok Cekmecelioglu B, et al. Liposomal bupivacaine, plain bupivacaine, and saline for transversus abdominis plane blocks: the CLEVELAND randomized trial. Anesthesiology 2026; 144: 546-58.
crossref pmid
29. Joshi GP, Mariano ER, Elkassabany NM, Harbell M, Johnson RL, Li J, et al. 2026 American Society of Anesthesiologists practice guideline on perioperative pain management using local and regional analgesia for cardiothoracic surgeries, mastectomy, and abdominal surgeries. Anesthesiology 2026; 144: 19-43.
crossref pmid
30. Carron M, Tamburini E, Linassi F, Pettenuzzo T, Boscolo A, Navalesi P. Efficacy of nonopioid analgesics and adjuvants in multimodal analgesia for reducing postoperative opioid consumption and complications in obesity: a systematic review and network meta-analysis. Br J Anaesth 2024; 133: 1234-49.
crossref pmid
31. Zhang F, Wang LY, Chen ZL, Cao XY, Chen BY. Cognitive behavioral therapy achieves better benefits in relieving postoperative pain and improving joint function: a systematic review and meta-analysis of randomized controlled trials. J Orthop Sci 2024; 29: 681-9.
crossref pmid
32. Waljee J, McGlinn EP, Sears ED, Chung KC. Patient expectations and patient-reported outcomes in surgery: a systematic review. Surgery 2014; 155: 799-808.
crossref pmid pmc
33. Dickerson DM, Mariano ER, Szokol JW, Harned M, Clark RM, Mueller JT, et al. Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder. Reg Anesth Pain Med 2024; 49: 716-24.
crossref
34. Fillingham YA, Hannon CP, Erens GA, Mullen K, Casambre F, Visvabharathy V, et al. The efficacy and safety of acetaminophen in total joint arthroplasty: systematic review and direct meta-analysis. J Arthroplasty 2020; 35: 2715-29.
crossref pmid
35. Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg 2017; 152: 691-7.
crossref pmid
36. Doleman B, Leonardi-Bee J, Heinink TP, Boyd-Carson H, Carrick L, Mandalia R, et al. Pre-emptive and preventive NSAIDs for postoperative pain in adults undergoing all types of surgery. Cochrane Database Syst Rev 2021; 6: CD012978.
crossref pmid pmc
37. Bongiovanni T, Lancaster E, Ledesma Y, Whitaker E, Steinman MA, Allen IE, et al. Systematic review and meta-analysis of the association between non-steroidal anti-inflammatory drugs and operative bleeding in the perioperative period. J Am Coll Surg 2021; 232: 765-90.e1.
crossref pmid pmc
38. Bell S, Rennie T, Marwick CA, Davey P. Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function. Cochrane Database Syst Rev 2018; 11: CD011274.
crossref pmid pmc
39. Kohan L, Potru S, Barreveld AM, Sprintz M, Lane O, Aryal A, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med 2021; 46: 840-59.
crossref pmid
40. Mariano ER, Schatman ME. A commonsense patient-centered approach to multimodal analgesia within surgical enhanced recovery protocols. J Pain Res 2019; 12: 3461-6.
crossref pmid pmc
41. Ilfeld BM. Continuous peripheral nerve blocks: An update of the published evidence and comparison with novel, alternative analgesic modalities. Anesth Analg 2017; 124: 308-35.
crossref pmid
42. Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev 2018; 6: CD009642.
crossref pmid pmc
43. Foo I, Macfarlane AJ, Srivastava D, Bhaskar A, Barker H, Knaggs R, et al. The use of intravenous lidocaine for postoperative pain and recovery: international consensus statement on efficacy and safety. Anaesthesia 2021; 76: 238-50.
crossref pmid pdf
44. Lovett-Carter D, Kendall MC, Park J, Ibrahim-Hamdan A, Crepet S, De Oliveira G. The effect of systemic lidocaine on post-operative opioid consumption in ambulatory surgical patients: a meta-analysis of randomized controlled trials. Perioper Med (Lond) 2021; 10: 11.
crossref pmid pmc pdf
45. Popa GM, Abu-Awwad SA, Abu-Awwad A, Marta CI, Bimbo-Szuhai E, Bontea MG, et al. Intravenous lidocaine for postoperative pain and recovery after robotic prostate adenomectomy: a retrospective observational cohort study. Medicina (Kaunas) 2025; 61: 2045.
crossref pmid pmc
46. Foong KW, Lo YL, Chaw SH, Loh PS. Perioperative plasma lidocaine concentrations and their impact on pain control. A systematic review and meta-analysis. Pain Manag 2025; 15: 1065-78.
crossref pmid pmc
47. Xu S, Hu S, Ju X, Li Y, Li Q, Wang S. Effects of intravenous lidocaine, dexmedetomidine, and their combination on IL-1, IL-6 and TNF-α in patients undergoing laparoscopic hysterectomy: a prospective, randomized controlled trial. BMC Anesthesiol 2021; 21: 3.
crossref pmid pmc pdf
48. de la Gala F, de la Fuente E, Piñeiro P, Reyes A, Duque P, Sánchez-Pedrosa G, et al. Effect of intraoperative paravertebral or intravenous lidocaine infusion on postoperative complications and inflammation after lung resection surgery: a randomised controlled trial. Br J Anaesth 2025; 135: 1297-306.
crossref pmid pmc
49. Levy N, Quinlan J, El-Boghdadly K, Fawcett WJ, Agarwal V, Bastable RB, et al. An international multidisciplinary consensus statement on the prevention of opioid-related harm in adult surgical patients. Anaesthesia 2021; 76: 520-36.
crossref pmid pdf
50. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016; 17: 131-57.
crossref pmid
51. Ul Haq MA, Najeeb S, Junaid W, Chaudhry R. US Food and Drug Administration approval of suzetrigine: a breakthrough in nonopioid pain management. Anesth Analg 2025; 141: e8-9.
crossref pmid
52. Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther 2025; 14: 655-74.
crossref pmid pmc pdf
53. Keam SJ. Suzetrigine: first approval. Drugs 2025; 85: 845-51.
crossref pmid pdf
54. Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, et al. Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology 2025; 142: 1085-99.
crossref pmid pmc
55. ClinicalTrials.gov. Evaluation of efficacy and safety of suzetrigine (SUZ) for pain associated with diabetic peripheral neuropathy [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2026 Mar 19]. Available from https://clinicaltrials.gov/study/NCT07231419

56. Dhaliwal JS, Spurling BC, Molla M. Duloxetine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan [cited 2026 Mar 19]. Available from https://www.ncbi.nlm.nih.gov/books/NBK549806/

57. Govil N, Arora P, Parag K, Tripathi M, Garg PK, Goyal T. Postoperative acute pain management with duloxetine as compared to placebo: a systematic review with meta-analysis of randomized clinical trials. Pain Pract 2023; 23: 818-37.
crossref pmid
58. Zhong H, Li J, Chen Y, Huang Y, Wen Z, Zhao J. Effect of duloxetine on pain and opioid consumption after total knee and hip arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Int J Clin Pharm 2024; 46: 14-25.
crossref pmid pdf
59. Azimi A, Hooshmand E, Mafi AA, Tabatabaei FS. Effect of duloxetine on opioid consumption and pain after total knee and hip arthroplasty: a systematic review and meta-analysis of randomized clinical trials. Pain Med 2023; 24: 1035-45.
crossref pmid pdf
60. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res 2013; 36: 237-51.
crossref pmid pdf
61. Chen Z, Chen J, Luo R, Jiang J, Xiang Z. The preemptive effects of oral pregabalin on perioperative pain management in lower limb orthopedic surgery: a systematic review and meta-analysis. J Orthop Surg Res 2022; 17: 237.
crossref pmid pmc pdf
62. Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States. JAMA Netw Open 2020; 3: e2031647.
crossref pmid pmc
63. Gandhi K, Schwenk ES. Pro-con debate on perioperative gabapentinoids: a nuanced approach is the best one. Reg Anesth Pain Med 2025. Advance Access published on Nov 5, 2025. doi: 10.1136/rapm-2025-107210.
crossref pmid
64. Campbell R, Khuong JN, Liu Z, Borg C, Jackson S, Ramson DM, et al. Perioperative gabapentinoid use lowers short-term opioid consumption following lower limb arthroplasty: systematic review and meta-analysis. J Opioid Manag 2021; 17: 251-72.
crossref pmid pdf
65. Liu B, Liu R, Wang L. A meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery. Medicine (Baltimore) 2017; 96: e8031.
crossref pmid pmc
66. Verret M, Lauzier F, Zarychanski R, Perron C, Savard X, Pinard AM, et al. Perioperative use of gabapentinoids for the management of postoperative acute pain: a systematic review and meta-analysis. Anesthesiology 2020; 133: 265-79.
crossref pmid
67. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 2018; 43: 521-46.
crossref pmid pmc
68. Hannon CP, Fillingham YA, Gililland JM, Sporer SM, Casambre FD, Verity TJ, et al. A systematic review of the efficacy and safety of ketamine in total joint arthroplasty. J Arthroplasty 2023; 38: 763-8.e2.
crossref pmid
69. Shen MR, Campbell DE, Kopczynski A, Maddams S, Rosenblum N, Nigam K, et al. Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review. Front Psychiatry 2025; 16: 1552084.
crossref pmid pmc
70. Guo J, Qiu D, Gu HW, Wang XM, Hashimoto K, Zhang GF, et al. Efficacy and safety of perioperative application of ketamine on postoperative depression: a meta-analysis of randomized controlled studies. Mol Psychiatry 2023; 28: 2266-76.
crossref pmid pmc pdf
71. Schwenk ES, Goldberg SF, Patel RD, Zhou J, Adams DR, Baratta JL, et al. Adverse drug effects and preoperative medication factors related to perioperative low-dose ketamine infusions. Reg Anesth Pain Med 2016; 41: 482-7.
crossref pmid
72. Rodríguez-Rubio L, Nava E, Del Pozo JS, Jordán J. Influence of the perioperative administration of magnesium sulfate on the total dose of anesthetics during general anesthesia. A systematic review and meta-analysis. J Clin Anesth 2017; 39: 129-38.
crossref pmid
73. Jin Z, Zhao J. Effectiveness and impact of intravenous magnesium sulfate in spinal surgery systematic review and meta-analysis. Front Pharmacol 2025; 16: 1624119.
crossref pmid pmc
74. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14: 145-61.
crossref pmid
75. Van Ryswyk E, Antic NA. Opioids and sleep-disordered breathing. Chest 2016; 150: 934-44.
crossref pmid
76. Goplen CM, Verbeek W, Kang SH, Jones CA, Voaklander DC, Churchill TA, et al. Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: a systematic review and meta-analysis. BMC Musculoskelet Disord 2019; 20: 234.
crossref pmid pmc pdf
77. Tefera YG, Gray S, Nielsen S, Collie A. Preoperative opioid use and postoperative return to work following spinal surgery in workers' compensation settings: a systematic review and meta-analysis. Int J Surg 2024; 110: 1781-92.
crossref pmid pmc
78. Vadeghani AT, Grant M, Forget P. Perioperative pain management interventions in opioid user patients: an overview of reviews. BMC Anesthesiol 2024; 24: 310.
crossref pmid pmc pdf
79. Coluzzi F, Bifulco F, Cuomo A, Dauri M, Leonardi C, Melotti RM, et al. The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag 2017; 13: 1163-73.
crossref pmid pmc pdf
80. Meyer-Frießem CH, Lipke E, Weibel S, Kranke P, Reichl S, Pogatzki-Zahn EM, et al. Perioperative ketamine for postoperative pain management in patients with preoperative opioid intake: a systematic review and meta-analysis. J Clin Anesth 2022; 78: 110652.
crossref pmid
81. Wenzel JT, Schwenk ES, Baratta JL, Viscusi ER. Managing opioid-tolerant patients in the perioperative surgical home. Anesthesiol Clin 2016; 34: 287-301.
crossref pmid
82. Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic [Internet]. Atlanta (GA): Centers for Disease Control and Prevention [cited 2026 Mar 19]. Available from https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html

83. Kohan L, Potru S, Barreveld AM, Sprintz M, Lane O, Aryal A, et al. Guidelines for the use of buprenorphine for opioid use disorder in the perioperative setting. Reg Anesth Pain Med 2021; 46: 860-1.
crossref pmid
84. Anderson TA, Quaye AN, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine. Anesthesiology 2017; 126: 1180-6.
crossref pmid pmc
85. Chang KY, Chang WK, Chang WL, Lin SM, Chan KH, Sung CS, et al. Comparison of intravenous patient-controlled analgesia with buprenorphine versus morphine after lumbar spinal fusion--a prospective randomized clinical trial. Acta Anaesthesiol Taiwan 2006; 44: 153-9.
pmid
86. Dingus DJ, Sherman JC, Rogers DA, DiPiro JT, May R, Bowden TA Jr. Buprenorphine versus morphine for patient-controlled analgesia after cholecystectomy. Surg Gynecol Obstet 1993; 177: 1-6.
pmid
87. Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011; 59: 385-90.
crossref pmid
88. Harrison TK, Kornfeld H, Aggarwal AK. Perioperative considerations for medications for opioid use disorder: buprenorphine, methadone, or naltrexone. Anesthesiol Clin 2025; 43: 645-58.
crossref pmid
89. Chitnis SS, Tang R, Mariano ER. The role of regional analgesia in personalized postoperative pain management. Korean J Anesthesiol 2020; 73: 363-71.
crossref pmid pmc pdf
90. Dickerson DM, Mariano ER, Schwenk ES. Multiorganizational consensus on principles for perioperative pain management for patients with chronic pain, opioid tolerance, and substance use disorder: an infographic. Reg Anesth Pain Med 2024; 49: 725.
crossref pmid
91. Ramo S, Frangakis S, Waljee JF, Bicket MC. Risk factors for persistent postoperative opioid use: an entity distinct from chronic postsurgical pain. Reg Anesth Pain Med 2025; 50: 121-8.
crossref pmid


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
101-3503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-792-5128    Fax: +82-2-792-4089    E-mail: journal@anesthesia.or.kr                
Business Name: Korean Society of Anesthesiologists
Business Registration: 106-82-07194
Representative: Young-Tae Jeon

Copyright © 2026 by Korean Society of Anesthesiologists.

Developed in M2PI

Close layer
prev next